No Data
No Data
Asymchem Laboratories (06821.HK) has received an increase in shareholding of 0.2392 million shares of Listed in Hong Kong by Norwegian Bank Investment Management, valued at approximately 13.2767 million Hong Kong dollars.
According to a report on May 9, based on documents disclosed by the Hong Kong Stock Exchange on May 9, Norges Bank Investment Management increased its stake in Asymchem Laboratories (06821.HK) by purchasing 239,200 shares of H Shares at an average price of HKD 55.5048 per share on May 7, for a total value of approximately HKD 13.2767 million. After the increase, Norges Bank Investment Management's latest shareholding number is 3.0973 million shares, with the proportion of holdings rising from 10.37% to 11.24%. Image Source: Stock Rights Disclosure from the Exchange What is equity disclosure? According to the Hong Kong Stock Exchange's requirements, major shareholders (holding 5% or more)
AI empowers the FDA! Drug approvals hit the 'fast-forward' button, and a large number of pharmaceutical companies may welcome a 'Gold' period.
The USA Food and Drug Administration (FDA) announced an accelerated plan on Thursday to fully implement AI applications across all subsidiary institutions by June 30, aiming to significantly expedite the approval process for new pharmaceuticals.
Asymchem Laboratories (06821.HK) received a Shareholding increase of 0.1605 million shares Listed in Hong Kong from Norwegian Banks Investment Management, valued at approximately 9.1254 million Hong Kong dollars.
On May 7, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on May 7, Norges Bank, the Norwegian Bank Investment Management, increased its shareholding on May 6 by 160,500 shares of H-shares of Asymchem Laboratories (06821.HK) at an average price of 56.856 HKD per share, valued at approximately 9.1254 million HKD. After the increase, Norges Bank's latest number of shares held is 2.8581 million shares, and the proportion of shares held rose from 9.79% to 10.37%. Image source: Shareholding disclosure from the Stock Exchange. Why does the investor increase their shareholding, but the proportion of shares held decreases? This may be due to the increase in the number of shares listed in Hong Kong.
Lobbyist groups warn that Trump's drug pricing proposal could lead to a loss of 1 trillion dollars for the pharmaceutical industry.
Lobbying groups warn that USA President Donald Trump's new pharmaceutical pricing proposal could result in losses of up to 1 trillion dollars for pharmaceutical companies over the next decade.
Hong Kong stocks movement | Trump predicts pharmaceutical tariffs, with pharmaceutical stocks generally declining. HBM HOLDINGS-B (02142) fell more than 7%.
Pharmaceutical stocks generally declined in the morning session. As of the time of writing, HBM HOLDINGS-B (02142) fell 7.06% to 8.04 Hong Kong dollars; JUNSHI BIO (01877) fell 6.38% to 14.98 Hong Kong dollars; REMEGEN (09995) fell 6.48% to 38.25 Hong Kong dollars.
Trump wants to impose tariffs on Pharmaceuticals: Pharmaceutical companies are busy stockpiling, and the import volume in the USA surged in March.
① The volume of Pharmaceutical imports in the USA surged in March, as pharmaceutical companies stockpiled products in anticipation of potential tariffs; ② A report released by the US Department of Commerce on Tuesday showed that the total value of Pharmaceutical imports in March exceeded 50 billion USD, equivalent to 20% of the total Pharmaceutical imports for the entire year of 2024.